Evidence map›Paper›PMID 36028552›Full record

Observational studyScientific reports2022

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.

Nieves Martínez-Lago, Teresa Calleja Chucla, Beatriz Alonso De Castro, Rafael Varela Ponte, Cristina Reboredo Rendo, Martin Igor Gomez-Randulfe Rodriguez, Sofia Silva Diaz, Begoña Graña Suarez, Juan de la Cámara Gomez, Fernando Busto Fernández and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Nieves Martínez-LagoMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain. Nieves.Purificacion.Martinez.Lago@sergas.es.ORCID 0000-0002-0408-6871
Teresa Calleja ChuclaPharmacy Department, University Hospital A Coruña, A Coruña, Spain.
Beatriz Alonso De CastroMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Rafael Varela PonteRadiology Department, University Hospital Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
Cristina Reboredo RendoMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Martin Igor Gomez-Randulfe RodriguezMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Sofia Silva DiazMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Begoña Graña SuarezMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Juan de la Cámara GomezMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Fernando Busto FernándezPharmacy Department, University Hospital A Coruña, A Coruña, Spain.
María Mateos SalvadorPharmacy Department, University Hospital A Coruña, A Coruña, Spain.
Margarita Reboredo LopezMedical Oncology Department, University Hospital A Coruña. Biomedical Research Institute (INIBIC, A Coruña), Xubias de Arriba, 84, 15006, A Coruña, Galicia, Spain.
Instituto de Investigación Biomédica de A Coruña · ESUniversidade da Coruña · ESUniversidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. Patients refractory or intolerant to standard therapies received TAS-102 (30-35 mg/m

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDrug CombinationsHumansMiddle AgedPrognosisPyrrolidinesRetrospective StudiesThymineTrifluridineUracilBevacizumabDrug CombinationsPyrrolidinesThyminetipiracilTrifluridinetrifluridine tipiracil drug combinationUracil

Identifiers

PMID36028552
PMCPMC9418211
OpenAlexW4293149746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.